Suven Life Sciences Ltd has secured patents in the US and New Zealand for one of its New Chemical Entities (NCE) for central nervous system therapy.
The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.
Histaminargic dysfunction has been strongly associated with the cognitive and behavioural deficits observed in several CNS disorders. H3 receptor blockade elevates acetylcholine in brain regions responsible for cognition, thus offering a means for targeting cognitive processes.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.